Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review - Top-Institutions - MDSpire

Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review

  • By

  • Lijun Shi

  • Zhongrui Ma

  • Xia Yu

  • Tian Wang

  • Li Wei

  • Yaning Pan

  • Tantian Jiang

  • Xiujin Wu

  • July 14, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology

  • #3

    Harvard Medical School
    Harvard Medical School

    Boston, Massachusetts

    Key Differentiators

    • Hematology

  • #4

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Hematology

Original Source(s)

Venetoclax combined with azacitidine in the treatment of secondary myelodysplastic syndrome following multiple myeloma: a case report and literature review

  • by Lijun Shi, Zhongrui Ma, Xia Yu, Tian Wang, Li Wei, Yaning Pan, Tantian Jiang, Xiujin Wu

  • July 14, 2026

Related Content

Navigating the gut–metabolite–immune axis: enhancing efficacy and mitigating toxicity of immune checkpoint inhibitors

Machine learning-driven identification of DLL3 as a molecular target and development of a DLL3-binding cyclic peptide for glioblastoma

EUS-guided transmural treatment of afferent loop syndrome: a systematic review and meta-analysis